The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
Abstract
Purpose: Combretastatin A4 (CA4) phosphate (CA4P) inhibits microtubule polymerization and is toxic to proliferating endothelial cells in vitro. It causes reversible vascular shutdown in established tumors in vivo, consistent with an antivascular mechanism of action. The present study investigated escalating doses of CA4P administered intravenously to patients with advanced cancer. Patients and Methods: Patients with solid malignancies and good performance status received CA4P as a 10-minute infusion daily for 5 days repeated every 3 weeks. Pharmacokinetic sampling was performed during cycle 1. Patients receiving ≥ 52 mg/m 2/d had serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies to measure changes in tumor perfusion with CA4P treatment. Results: Thirty-seven patients received 133 treatment cycles. CA4P dose levels ranged from 6 mg/m 2 to 75 mg/m 2 daily. Severe pain at sites of known tumor was dose limiting at 75 mg/m 2. Dose-limiting cardiopulmonary toxicity (syncope and dyspnea or hypoxia) was noted as well in two patients treated at 75 mg/m 2. Other toxicities included hypotension, ataxia, dyspnea, nausea or vomiting, headache, and transient sensory neuropathy. Plasma CA4P and CA4 area under the concentration-time curve and maximal concentration values increased linearly with dose. Tumor perfusion, as measured by the first-order rate constant of gadolinium plasma to tissue transfer during DCE-MRI studies, was found to decrease in eight of 10 patients. Relationships were also demonstrated between perfusion changes and pharmacokinetic indices. A partial response was observed in a patient with metastatic soft tissue sarcoma, and 14 patients exhibited disease stability for a minimum of two cycles. Conclusion: Doses of CA4P on a daily times five schedule of 52 to 65 mg/m 2 were reasonably well-tolerated. The 52 mg/m 2 dose is recommended for further study based on cumulative phase I experience with CA4P. Antitumor efficacy was observed, and the use of DCE-MRI provided a valuable noninvasive measure of the vascular effects of CA4P treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143
Tofts, P. S., & Kermode, A. G. (1991) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910170208 · Cited by 1,456
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., & Garcia-Kendal, D. (1989) · Experientia · doi:10.1007/bf01954881 · Cited by 786
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Self-citationDowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 403
Self-citationKey factors in the acquisition of contrast kinetic data for oncology
Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<254::aid-jmri5>3.0.co;2-9 · Cited by 369
Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
Denekamp, J. (1993) · The British Journal of Radiology · doi:10.1259/0007-1285-66-783-181 · Cited by 358
Galbraith, S. M., Lodge, M. A., Taylor, N. J., Rustin, G. J. S., Bentzen, S., Stirling, J. J., & Padhani, A. R. (2002) · NMR in Biomedicine · doi:10.1002/nbm.731 · Cited by 338
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
Self-citationDonahue, K. M., Krouwer, H. G. J., Rand, S. D., Pathak, A. P., Marszalkowski, C. S., Censky, S. C., & Prost, R. W. (2000) · Magnetic Resonance in Medicine · doi:10.1002/1522-2594(200006)43:6<845::aid-mrm10>3.0.co;2-j · Cited by 253
Padhani, A. R., & Husband, J. E. (2001) · Clinical Radiology · doi:10.1053/crad.2001.0762 · Cited by 230
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., & Bibby, M. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6692174 · Cited by 213
The interaction with tubulin of a series of stilbenes based on combretastatin A-4
Woods, J., Hadfield, J., Pettit, G., Fox, B., & McGown, A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.138 · Cited by 175
Vinca alkaloids: Anti-vascular effects in a murine tumour
Hill, S. A., Lonergan, S. J., Denekamp, J., & Chaplin, D. J. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90082-q · Cited by 168
Self-citationPixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer
Mayr, N. A., Yuh, W. T. C., Arnholt, J. C., Ehrhardt, J. C., Sorosky, J. I., Magnotta, V. A., Berbaum, K. S., Zhen, W. K., Paulino, A. C., Oberley, L. W., et al. (2000) · Journal of Magnetic Resonance Imaging · doi:10.1002/1522-2586(200012)12:6<1027::aid-jmri31>3.0.co;2-5 · Cited by 165
Iyer, S., Chaplin, D. J., Rosenthal, D. S., et al. (1998) · PubMed · Cited by 147
Self-citationLi, L., Rojiani, A. M., & Siemann, D. W. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00320-4 · Cited by 130
Beauregard, D. A., Thelwall, P., Chaplin, D. J., Hill, S., Adams, G., & Brindle, K. M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.294 · Cited by 99
Self-citationGrosios, K., Loadman, P. M., Swaine, D. J., et al. (2000) · PubMed · Cited by 81
Alteration of microtubule polymerization modulates arteriolar vasomotor tone
Platts, S. H., Falcone, J. C., Holton, W. T., Hill, M. A., & Meininger, G. A. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.277.1.h100 · Cited by 61
Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
Griggs, J., Hesketh, R., Smith, G. A., Brindle, K. M., Metcalfe, J. C., Thomas, G. A., & Williams, E. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1653 · Cited by 47
Stevenson, J. P., Sun, W., Gallagher, M., Johnson, R., Vaughn, D. J., Schuchter, L. M., Algazy, K., Hahn, S. M., Enas, N. H., Ellis, D., et al. (2002) · PubMed · Cited by 44
Self-citation
Cited by
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
An overview of tubulin inhibitors that interact with the colchicine binding site
Lu, Y., Chen, J., Xiao, M., Li, W., & Miller, D. D. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0828-z · Cited by 709
Medicinal Chemistry of Combretastatin A4: Present and Future Directions
Tron, G. C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., & Genazzani, A. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512903 · Cited by 629
Metadata
- Authors
- Stevenson, J. P., Rosen, M., Sun, W., Gallagher, M., Haller, D. G., Vaughn, D., Giantonio, B., Zimmer, R., Petros, W. P., Stratford, M., Chaplin, D., Young, S. L., Schnall, M., & O’Dwyer, P. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-01
- Volume
- 21
- Issue
- 23
- Pages
- 4428-4438
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152961487
- Cited by
- 291
- References
- 26
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.